Metabolic reprogramming of peritoneal mesothelial cells in peritoneal dialysis–associated fibrosis: therapeutic targets and strategies
Abstract Peritoneal dialysis (PD) is considered a life-saving treatment for end-stage renal disease. However, prolonged PD use can lead to the development of peritoneal fibrosis (PF), diminishing its efficacy. Peritoneal mesothelial cells (PMCs) are key initiators of PF when they become damaged. Exp...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Cell Communication and Signaling |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12964-025-02113-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850127911293550592 |
|---|---|
| author | Fang Yu Jia Chen Xiaoyue Wang Shihui Hou Hong Li Yaru Yao Yani He Kehong Chen |
| author_facet | Fang Yu Jia Chen Xiaoyue Wang Shihui Hou Hong Li Yaru Yao Yani He Kehong Chen |
| author_sort | Fang Yu |
| collection | DOAJ |
| description | Abstract Peritoneal dialysis (PD) is considered a life-saving treatment for end-stage renal disease. However, prolonged PD use can lead to the development of peritoneal fibrosis (PF), diminishing its efficacy. Peritoneal mesothelial cells (PMCs) are key initiators of PF when they become damaged. Exposure to high glucose‑based peritoneal dialysis fluids (PDFs) contributes to PF development by directly affecting highly metabolically active PMCs. Recent research indicates that PMCs undergo metabolic reprogramming when exposed to high-glucose PDFs, including enhanced glycolysis, impaired oxidative phosphorylation, abnormal lipid metabolism, and mitochondrial dysfunction. Although this metabolic transition temporarily compensates for the cellular damage and maintains energy levels, its long-term impact on peritoneal tissue is concerning. Multiple studies have identified a close association between this shift in energy metabolism and PF, and may promote the progression of PF through various molecular mechanisms. This review explores recent findings regarding the role and mechanism of PMC metabolic reprogramming in PF progression. Moreover, it provides a summary of potential therapeutic strategies aimed at various metabolic processes, including glucose metabolism, lipid metabolism, and mitochondrial function. The review establishes that targeting metabolic reprogramming in PMCs may be a novel strategy for preventing and treating PD-associated fibrosis. |
| format | Article |
| id | doaj-art-ce25bea027aa4877930a2d0f67b2050a |
| institution | OA Journals |
| issn | 1478-811X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Cell Communication and Signaling |
| spelling | doaj-art-ce25bea027aa4877930a2d0f67b2050a2025-08-20T02:33:32ZengBMCCell Communication and Signaling1478-811X2025-02-0123111710.1186/s12964-025-02113-2Metabolic reprogramming of peritoneal mesothelial cells in peritoneal dialysis–associated fibrosis: therapeutic targets and strategiesFang Yu0Jia Chen1Xiaoyue Wang2Shihui Hou3Hong Li4Yaru Yao5Yani He6Kehong Chen7Department of Nephrology, Daping Hospital, Army Medical Center, Army Medical UniversityDepartment of Nephrology, Daping Hospital, Army Medical Center, Army Medical UniversityDepartment of Nephrology, Daping Hospital, Army Medical Center, Army Medical UniversityDepartment of Nephrology, Daping Hospital, Army Medical Center, Army Medical UniversityDepartment of Nephrology, Daping Hospital, Army Medical Center, Army Medical UniversityDepartment of Nephrology, Daping Hospital, Army Medical Center, Army Medical UniversityDepartment of Nephrology, Daping Hospital, Army Medical Center, Army Medical UniversityDepartment of Nephrology, Daping Hospital, Army Medical Center, Army Medical UniversityAbstract Peritoneal dialysis (PD) is considered a life-saving treatment for end-stage renal disease. However, prolonged PD use can lead to the development of peritoneal fibrosis (PF), diminishing its efficacy. Peritoneal mesothelial cells (PMCs) are key initiators of PF when they become damaged. Exposure to high glucose‑based peritoneal dialysis fluids (PDFs) contributes to PF development by directly affecting highly metabolically active PMCs. Recent research indicates that PMCs undergo metabolic reprogramming when exposed to high-glucose PDFs, including enhanced glycolysis, impaired oxidative phosphorylation, abnormal lipid metabolism, and mitochondrial dysfunction. Although this metabolic transition temporarily compensates for the cellular damage and maintains energy levels, its long-term impact on peritoneal tissue is concerning. Multiple studies have identified a close association between this shift in energy metabolism and PF, and may promote the progression of PF through various molecular mechanisms. This review explores recent findings regarding the role and mechanism of PMC metabolic reprogramming in PF progression. Moreover, it provides a summary of potential therapeutic strategies aimed at various metabolic processes, including glucose metabolism, lipid metabolism, and mitochondrial function. The review establishes that targeting metabolic reprogramming in PMCs may be a novel strategy for preventing and treating PD-associated fibrosis.https://doi.org/10.1186/s12964-025-02113-2Metabolic reprogrammingPeritoneal mesothelial cellsPeritoneal dialysisPeritoneal fibrosisTherapeutic target |
| spellingShingle | Fang Yu Jia Chen Xiaoyue Wang Shihui Hou Hong Li Yaru Yao Yani He Kehong Chen Metabolic reprogramming of peritoneal mesothelial cells in peritoneal dialysis–associated fibrosis: therapeutic targets and strategies Cell Communication and Signaling Metabolic reprogramming Peritoneal mesothelial cells Peritoneal dialysis Peritoneal fibrosis Therapeutic target |
| title | Metabolic reprogramming of peritoneal mesothelial cells in peritoneal dialysis–associated fibrosis: therapeutic targets and strategies |
| title_full | Metabolic reprogramming of peritoneal mesothelial cells in peritoneal dialysis–associated fibrosis: therapeutic targets and strategies |
| title_fullStr | Metabolic reprogramming of peritoneal mesothelial cells in peritoneal dialysis–associated fibrosis: therapeutic targets and strategies |
| title_full_unstemmed | Metabolic reprogramming of peritoneal mesothelial cells in peritoneal dialysis–associated fibrosis: therapeutic targets and strategies |
| title_short | Metabolic reprogramming of peritoneal mesothelial cells in peritoneal dialysis–associated fibrosis: therapeutic targets and strategies |
| title_sort | metabolic reprogramming of peritoneal mesothelial cells in peritoneal dialysis associated fibrosis therapeutic targets and strategies |
| topic | Metabolic reprogramming Peritoneal mesothelial cells Peritoneal dialysis Peritoneal fibrosis Therapeutic target |
| url | https://doi.org/10.1186/s12964-025-02113-2 |
| work_keys_str_mv | AT fangyu metabolicreprogrammingofperitonealmesothelialcellsinperitonealdialysisassociatedfibrosistherapeutictargetsandstrategies AT jiachen metabolicreprogrammingofperitonealmesothelialcellsinperitonealdialysisassociatedfibrosistherapeutictargetsandstrategies AT xiaoyuewang metabolicreprogrammingofperitonealmesothelialcellsinperitonealdialysisassociatedfibrosistherapeutictargetsandstrategies AT shihuihou metabolicreprogrammingofperitonealmesothelialcellsinperitonealdialysisassociatedfibrosistherapeutictargetsandstrategies AT hongli metabolicreprogrammingofperitonealmesothelialcellsinperitonealdialysisassociatedfibrosistherapeutictargetsandstrategies AT yaruyao metabolicreprogrammingofperitonealmesothelialcellsinperitonealdialysisassociatedfibrosistherapeutictargetsandstrategies AT yanihe metabolicreprogrammingofperitonealmesothelialcellsinperitonealdialysisassociatedfibrosistherapeutictargetsandstrategies AT kehongchen metabolicreprogrammingofperitonealmesothelialcellsinperitonealdialysisassociatedfibrosistherapeutictargetsandstrategies |